A point-of-care exhaled breath condensate device combined with physiological parameters and ensemble machine learning identified early-stage lung cancer in a real-world screening cohort with 85.7% accuracy and 100% specificity on held-out test data.
Researchers tested Inflammacheck, a point-of-care device that measures hydrogen peroxide in exhaled breath condensate plus physiological signals, combined with machine learning, in 34 participants from a UK lung health check programme where 83% of cancers were stage I-II. Multivariate analyses separated cancer and control groups, and a voting ensemble achieved 85.7% accuracy and 0.90 ROC-AUC on held-out data.
- Impact 30%
- 69
- Evidence 25%
- 95
- Scale 20%
- 35
- Confidence 15%
- 87
- Recency 10%
- 86
Updated Aug 1, 2026 · TRV-2026-0616
ace